Abstract:INTRODUCTION:Neoadjuvant chemotherapy is the treatment of choice for patients with locally advanced breast cancer, however, because of tumor heterogeneity, not all tumors will respond to this treatment. In this context, we evaluated the EZH2 protein (Enhancer of Zest Homolog 2), a histone methyltransferase. EZH2 catalyses the trimethylation of lysine 27 of histone H3. The purposes of this study were to evaluate the expression of EZH2 for predicting tumor response to neoadjuvant chemotherapy in locally advanced… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.